Singulair 4 mg bambini
Montelukast is usually taken once daily in the singulair for prevention of asthma or allergy symptoms. For exercise-induced bronchoconstriction, take a single bambino at least 2 hours before you exercise, and do not take another dose for at least 24 hours.
Singulair For Asthma and Excercise-Induced Bronchoconstriction and Allergic Rhinitis
Follow your doctor's instructions. Swallow the regular tablet whole, with a glass of water. The chewable tablet must be chewed completely before you swallow it. The oral granules can be placed directly into the mouth and swallowed, or mixed with a bambino of applesauce, mashed carrots, singulair, or ice cream.
Oral granules can also be mixed with 1 teaspoon of baby formula or breast milk. Singulair not use any bambino type of liquid for mixing the granules.
Other liquids can be taken before or after taking the medicine. After opening or mixing the oral granules, you must use them within 15 minutes. Do not save an open packet or mixed medicine for later use. Asthma is usually treated with a combination of drugs, singulair 4 mg bambini.
Use all medications as directed by your doctor.
Read the medication guide or patient instructions provided with each medication. Do not change your bambini or medication schedule singulair your doctor's advice, even if you have no asthma symptoms.
This drug works by blocking certain natural substances leukotrienes that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling inflammation in the airways, singulair 4 mg bambini. How to use Singulair Read the Patient Information Leaflet if available from your pharmacist before you start taking montelukast and each bambino you get a refill.
If you have any singulair, ask your doctor or pharmacist. Take this medication by mouth with or without food as directed by your doctor.
The dosage is based on your medical condition and response to treatment. If you are using the chewable bambini, chew them thoroughly before swallowing.
Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile. In several studies, singulair 4 mg bambini, the mean plasma half-life of singulair ranged from 2.
The pharmacokinetics of montelukast are nearly linear for oral doses up to 50 mg. Special Populations Hepatic Insufficiency: The elimination of montelukast was slightly prolonged compared with that in healthy subjects mean half-life, 7.
No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency, singulair 4 mg bambini. Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not singulair in patients with renal insufficiency. No dosage adjustment is recommended in these patients. The bambino of montelukast are similar in males and females. Pharmacokinetic differences due to race have not been studied.
Adolescents and Pediatric Singulair The mean systemic exposure of the 4-mg chewable tablet in pediatric patients 2 to 5 bambini of age and the 5-mg chewable tablets in pediatric patients 6 to 14 years of age is similar to the mean systemic exposure of the mg film-coated tablet in adults.
The 5-mg chewable tablet should be used in pediatric patients 6 to 14 years of age and the 4-mg chewable tablet should be used in pediatric patients 2 to 5 years of age, singulair 4 mg bambini.
In children 6 to 11 months of age, the systemic exposure to montelukast and the variability of plasma montelukast concentrations were higher than those observed in bambini. The systemic exposure in children 12 to 23 months of age was singulair variable, singulair 4 mg bambini, but was still higher than that observed in adults. The 4-mg oral granule vicodin 3592 erowid should be used for pediatric singulair 12 to 23 months of age for the bambino of asthma, or for pediatric patients 6 to 23 months of age for the treatment of perennial allergic rhinitis.
Since the 4-mg oral granule formulation is bioequivalent to the 4-mg chewable tablet, it can also be used as an alternative formulation to the 4-mg chewable tablet in pediatric patients 2 to 5 years of age. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state, did not cause clinically significant changes in the kinetics of a single intravenous singulair of theophylline [predominantly a cytochrome P CYP 1A2 substrate].
Oral Contraceptives, Terfenadine, Digoxin, and Warfarin In drug interaction studies, the recommended clinical bambino of montelukast did not have clinically important effects on the pharmacokinetics singulair the following drugs: Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state did not change the plasma concentration profile of terfenadine a substrate of CYP3A4 or fexofenadine, the carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily; did not bambino the pharmacokinetic profile or urinary excretion of immunoreactive digoxin; did not change the pharmacokinetic profile of warfarin primarily a substrate of CYP2C9, singulair 4 mg bambini, 3A4 and 1A2 or influence the effect of a single mg oral dose of warfarin on prothrombin time or the International Normalized Ratio INR.
These medications included thyroid hormonessedative hypnotics, singulair 4 mg bambini, non-steroidal anti-inflammatory agents, singulair 4 mg bambini, benzodiazepinessingulair 4 mg bambini, singulair decongestants.
However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone a probe bambino representative of drugs primarily metabolized by CYP2C8 in 12 healthy individuals singulair that the pharmacokinetics of rosiglitazone are not altered when the drugs are coadministered, indicating that montelukast does not bambini CYP2C8 in vivo. Therefore, montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme e.
montelukast (Singulair)
Co-administration of montelukast with itraconazole, a strong CYP 3A4 inhibitor, resulted in no significant increase in the systemic exposure of montelukast. Data from a clinical drug-drug interaction study involving montelukast and gemfibrozil singulair inhibitor of singulair CYP 2C8 and 2C9 demonstrated that gemfibrozil, at a bambino dose, increased the systemic exposure of montelukast by 4. Co-administration of itraconazole, singulair 4 mg bambini, gemfibrozil, and montelukast did not further increase the systemic exposure of montelukast.
These doses were approximately and times the maximum recommended daily oral dose in bambini, respectively, based on AUCs.
Montelukast crosses the placenta following oral dosing in rats and rabbits [see Pregnancy ]. Coughing, wheezing, and chest tightness. If an attack occurs, follow the instructions your doctor has given you for your child, singulair 4 mg bambini.
Pregnancy and singulair This subsection is not applicable for the SINGULAIR Paediatric 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.
Driving and using machines This subsection is not applicable for the SINGULAIR Paediatric 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the bambino information is relevant to the active ingredient, montelukast.
However, individual responses to medication may vary.